NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

06/26/2024
- AI
- Cardiology
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication i...
06/25/2024
- Cardiology
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. As part of this collaboration, Tempus will...
03/09/2023
- Cardiology
Tempus Announces the Acquisition of Mpirik

Tempus expands further into revolutionizing cardiovascular disease care Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the acquisition of Mpirik, a cardiology-focused healthcare technology company specializing in data-driven patient screening, automated care coordination, and clinical research. The combination of Mpirik's Cardiac Intelligence® platform...
11/04/2022
- Cardiology
Tempus Announces Six Abstracts Accepted for Presentation at the American Heart Association Scientific Sessions 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts, resulting from its strategic partnership with Geisinger, were accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2022, which convenes in Chicago, Illinois from November 5-7, 2022. This is the fourth year that Tempus has presented w...
11/03/2022
- AI
- Cardiology
Tempus Launches First Cardiology Prospective Study for its AI-Enabled Predictive Tests

In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of a multi-center study titled, ...
05/25/2022
- AI
- Cardiology
Tempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease

Published in Circulation, the rECHOmmend study expands on AI-focused research to improve patient outcomes in cardiology A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnosed structural heart disease....
03/05/2021
- Cardiology
- Clinical Trials
Researchers Find AI Can Predict New Atrial Fibrillation, Stroke Risk

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used el...
12/10/2020
- Cardiology
Tempus Announces $200 Million Series G-2 Financing

Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price....
03/13/2020
- Cardiology
Tempus Announces $100 Million in Series G Financing

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced an additional $100 million financing at a post-money valuation of $5 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price. ...
01/20/2020
- Cardiology
- Genomic Sequencing
Tempus Unveils AI-Enabled Smart Tests Across Disease Types

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, unveils its AI-enabled laboratory test (smart test) platform. Through its technology, laboratory tests are now able to be embedded with real-world evidence that deliver real-time, actionable insights to physicians, providing critical information...

1 2